1. China Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Shanghai Sanyou Medical Co. Ltd. Class A

Shanghai Sanyou Medical Co. Ltd. Class A

SSSE:688085
12.73
CNY
+0.32
(+2.58%)
4.39BMarket Cap
Oct 27Next Earn
Shanghai Sanyou Medical Co. Ltd. Class A
SSE:688085
(Shanghai Stock Exchange)

Recent

price

12.73

P/E

ratio

- -

div

yld

0.14%

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.3
0.67
0.9
1.45
1.3
1.82
1.98
1.39
1.44
1.49
- -
Revenue per Share
0.01
0.03
0.25
0.4
0.39
0.57
0.58
0.29
0.04
0.17
- -
Basic EPS, GAAP
0.06
-0.07
-0.16
-0.07
0.16
0.16
0.05
0.73
-0.08
0.11
- -
Free Cash Flow per Basic Share
- -
- -
0.04
- -
- -
0.11
0.11
0.06
0.07
0.01
0.02
Dividend per Share
0.71
1.18
1.38
1.78
4.68
5.14
5.61
5.84
5.83
5.74
5.84
Book Value per Share
0.7
1.08
1.29
1.69
4.61
4.08
4.52
4.62
4.5
4.53
4.65
Tangible Book Value per Share
250
208
248
244
301
326
327
332
315
365
372
Basic Weighted Avg Shares
75
140
222
354
390
593
649
460
454
543
- -
Sales/Revenue/Turnover
13.57
7.55
31.66
32.4
28.82
25.72
29.11
24.77
6.04
14.87
- -
Operating Margin (%)
5
5
6
6
10
15
19
30
38
38
- -
Depreciation Expense
3
5
62
98
119
186
191
96
11
63
- -
Net Income, GAAP
- -
50.11
13.52
13.95
13.43
10.21
15.02
15.74
44.7
18.69
- -
Effective Tax Rate (%)
4.16
3.72
27.95
27.61
30.37
31.41
29.39
20.76
2.53
11.63
- -
Profit Margin (%)
122
225
226
237
1,316
916
749
752
809
950
965
Working Capital
- -
- -
- -
- -
2
2
2
1
16
9
5
LT Debt
158
289
340
438
1,534
1,736
1,913
2,043
2,049
2,125
2,157
Total Equity
- -
1.8
18.66
24.02
11.36
11.07
10.56
5.12
0.56
1.94
- -
Return on Invested Capital (%)
- -
2.43
19.73
25.04
11.75
10.84
9.74
3.92
0.55
3.87
- -
Return on Capital (%)
- -
2.33
19.74
25.14
12.02
11.58
10.82
5.09
0.6
3.14
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
33
32
30
LT Borrowings
2
1
- -
LT Finance Leases
7
5
4
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
367
367
367
Market Capitalization
6,009
6,212
4,391

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,178
1,141
1,178
Cash, Cash Equivalents & STI
576
528
540
Accounts Receivable, Net
97
97
104
Inventories
283
288
302
Total Current Liabilities
228
195
213
Payables & Accruals
- -
- -
- -
ST Debt
33
32
30
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
6.83%
3.71%
Free Cash Flow
- -
169.28%
-247.61%
Net Income, GAAP
- -
74.38%
450.2%
Sales/Revenue/Turnover
- -
10.09%
19.66%
Total Cash Common Dividend
- -
- -
-90.56%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
86
126
121
121
454
2025
116
133
- -
151
543
2026
124
150
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.01
0.01
0.02
0.01
0.04
2025
0.04
0.06
- -
- -
0.17
2026
0.02
0.06
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.06
- -
- -
0.07
2025
- -
- -
- -
- -
0.01
2026
- -
0.02
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Shanghai Sanyou Medical Co., Ltd. engages primarily in the research, development, manufacturing, and sales of orthopedic implant consumables and ultrasonic power equipment; its core products encompass spinal implant consumables including anterior cervical plates, anterior thoracolumbar systems, posterior cervical systems, posterior thoracolumbar systems, and Z-minimally invasive products under the Tytus and Sanyou brands; trauma implant consumables such as shoulder and elbow systems, hip and pelvis systems, knee systems, and palm and wrist systems; vertebroplasty consumables; ultrasonic bone dynamic systems; ultrasonic hemostats; ultrasonic suction knives; and supporting surgical tools. Founded in 2005 and headquartered at No. 1988 Jiatang Road in Jiading District, Shanghai, China, with an additional facility at 385 Huirong Road in Jiading Industrial Zone, the company operates mainly in the domestic Chinese market while expanding overseas sales, particularly noted in recent revenue from international channels; it employs approximately 514 staff and focuses on high-value medical orthopedic segments targeting hospitals in orthopedics, neurosurgery, and hepatobiliary surgery. Recent major developments include plans announced in late 2024 to acquire the remaining 48.18% equity in controlling subsidiary Beijing Shuimu Tianpeng Medical Technology Co., Ltd. for approximately 416 million yuan via share issuance, cash, and private placement raising 214 million yuan, aiming to achieve 100% ownership, enhance strategic synergy in ultrasonic products, and boost consolidated profitability amid spinal consumables procurement pressures; earlier in August 2024, it increased its stake in Jiaoying Medical Devices Co., Ltd. by 4.75%; the company also maintains a historical technological partnership with Implanet for spinal products distribution in China since 2022.